Antiproliferative Effects of Somatostatin Analogs in Pituitary Adenomas

Overview

Journal Pituitary

Specialty Endocrinology

Date 2006 May 17

PMID 16703406

Citations 6

Authors

Maria Chiara Zatelli

Daniela Piccin

Maria Rosaria Ambrosio

Marta Bondanelli

Ettore C Degli Uberti

Affiliations

Soon will be listed here.

Abstract

The antisecretory effects of somatostatin (SRIF) and its analogs are widely recognised and provide the basis for treatment of hormonal hypersecretion in pituitary adenomas, especially in the settings of acromegaly. Evidence for an antiproliferative effect of these compounds has also been provided. This review focuses on the mechanisms transducing the antiproliferative effects of SRIF and its analogs on pituitary adenomas, and on the clinical consequences on tumor volume of pharmacological treatment of pituitary adenomas with these drugs.

Citing Articles

Somatostatin and Somatostatin Receptors in Tumour Biology.

Kumar U Int J Mol Sci. 2024; 25(1).

PMID: 38203605 PMC: 10779198. DOI: 10.3390/ijms25010436.

Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines.

Dicitore A, Saronni D, Gaudenzi G, Carra S, Cantone M, Borghi M J Endocrinol Invest. 2021; 45(1):29-41.

PMID: 34128215 PMC: 8741688. DOI: 10.1007/s40618-021-01609-1.

Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Gruppetta M, Formosa R, Falzon S, Ariff Scicluna S, Falzon E, Degeatano J Pituitary. 2017; 20(3):358-371.

PMID: 28342098 DOI: 10.1007/s11102-017-0803-0.

Antiproliferative effects of somatostatin analogs in endocrine tumours.

Zatelli M F1000 Med Rep. 2010; 1.

PMID: 20948740 PMC: 2924708. DOI: 10.3410/M1-40.

Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.

Feelders R, Hofland L, van Aken M, Neggers S, Lamberts S, de Herder W Drugs. 2009; 69(16):2207-26.

PMID: 19852525 DOI: 10.2165/11318510-000000000-00000.

References

Rocheville M, Lange D, Kumar U, Sasi R, Patel R, Patel Y . Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem. 2000; 275(11):7862-9. DOI: 10.1074/jbc.275.11.7862. View

Weckbecker G, Lewis I, Albert R, Schmid H, Hoyer D, Bruns C . Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003; 2(12):999-1017. DOI: 10.1038/nrd1255. View

van der Hoek J, de Herder W, Feelders R, van der Lely A, Uitterlinden P, Boerlin V . A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab. 2004; 89(2):638-45. DOI: 10.1210/jc.2003-031052. View

Dasgupta P, Singh A, Mukherjee R . Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin. Biochem Biophys Res Commun. 1999; 259(2):379-84. DOI: 10.1006/bbrc.1999.0773. View

Ezzat S, Horvath E, Harris A, Kovacs K . Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab. 1994; 79(1):113-8. DOI: 10.1210/jcem.79.1.8027215. View

Guillemin R . Peptides in the brain: the new endocrinology of the neuron. Science. 1978; 202(4366):390-402. DOI: 10.1126/science.212832. View

Patel Y, Wheatley T . In vivo and in vitro plasma disappearance and metabolism of somatostatin-28 and somatostatin-14 in the rat. Endocrinology. 1983; 112(1):220-5. DOI: 10.1210/endo-112-1-220. View

Greenman Y, Melmed S . Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab. 1994; 79(3):724-9. DOI: 10.1210/jcem.79.3.7521350. View

Gasperi M, Petrini L, Pilosu R, Nardi M, Marcello A, Mastio F . Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. J Endocrinol Invest. 1993; 16(7):541-3. DOI: 10.1007/BF03348901. View

10.

Cristina C, Diaz-Torga G, Baldi A, GONGORA A, Rubinstein M, Low M . Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology. 2005; 146(7):2952-62. DOI: 10.1210/en.2004-1445. View

11.

An J, Cho S, Jeong D, Park K, Ahn Y, Baik J . Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol. 2003; 206(1-2):49-62. DOI: 10.1016/s0303-7207(03)00236-3. View

12.

Culler M . Evolving concepts in the quest for advanced therapeutic analogues of somatostatin. Dig Liver Dis. 2004; 36 Suppl 1:S17-25. DOI: 10.1016/j.dld.2003.11.009. View

13.

Cap J, Cerman J, Nemecek S, Marekova M, Hana V, Frysak Z . The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas. J Clin Neurosci. 2003; 10(4):444-8. DOI: 10.1016/s0967-5868(03)00072-9. View

14.

Koper J, Hofland L, Van Koetsveld P, den Holder F, Lamberts S . Desensitization and resensitization of rat pituitary tumor cells in long-term culture to the effects of the somatostatin analogue SMS 201-995 on cell growth and prolactin secretion. Cancer Res. 1990; 50(19):6238-42. View

15.

Tauber J, Babin T, Tauber M, Vigoni F, Bonafe A, DuCasse M . Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab. 1989; 68(5):917-24. DOI: 10.1210/jcem-68-5-917. View

16.

Greenman Y, Melmed S . Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab. 1994; 78(2):398-403. DOI: 10.1210/jcem.78.2.8106629. View

17.

Delesque N, Buscail L, Esteve J, Saint-Laurent N, Muller C, Weckbecker G . sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res. 1997; 57(5):956-62. View

18.

Miller G, Alexander J, Bikkal H, Katznelson L, Zervas N, Klibanski A . Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab. 1995; 80(4):1386-92. DOI: 10.1210/jcem.80.4.7714115. View

19.

Moyse E, Le Dafniet M, Epelbaum J, Pagesy P, Peillon F, Kordon C . Somatostatin receptors in human growth hormone and prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab. 1985; 61(1):98-103. DOI: 10.1210/jcem-61-1-98. View

20.

Bevan J, BURKE C . Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol (Oxf). 1986; 25(5):561-72. DOI: 10.1111/j.1365-2265.1986.tb03610.x. View